A CRISPR screen identifies MAPK7 as a target for combination with MEK inhibition in KRAS mutant NSCLC.
Mutant KRAS represents one of the most frequently observed oncogenes in NSCLC, yet no therapies are approved for tumors that express activated KRAS variants. While there is strong rationale for the use of MEK inhibitors to treat tumors with activated RAS/MAPK signaling, these have proven ineffective...
Main Authors: | Nicholas Dompe, Christiaan Klijn, Sara A Watson, Katherine Leng, Jenna Port, Trinna Cuellar, Colin Watanabe, Benjamin Haley, Richard Neve, Marie Evangelista, David Stokoe |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2018-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC6005515?pdf=render |
Similar Items
-
Altered Transcriptional Control Networks with Trans-Differentiation of Isogenic Mutant KRas NSCLC Models
by: John A Haley, et al.
Published: (2014-12-01) -
RAF Suppression Synergizes with MEK Inhibition in KRAS Mutant Cancer Cells
by: Simona Lamba, et al.
Published: (2014-09-01) -
Targeted inhibition of glutamine metabolism enhances the antitumor effect of selumetinib in KRAS-mutant NSCLC
by: Meng Xia, et al.
Published: (2021-01-01) -
Macrophage migration inhibitory factor promotes resistance to MEK blockade in KRAS mutant colorectal cancer cells
by: Seul‐Ki Cheon, et al.
Published: (2018-08-01) -
Inhibition of lncRNA PART1 Chemosensitizes Wild Type but Not KRAS Mutant NSCLC Cells
by: Chen SC, et al.
Published: (2020-06-01)